Lower ARV formulations and reduced operating leverage hurt earnings

Company
26 Jul 2024
5 Min read 
  • Laurus Labs 1QFY25 results update in healthcare sector.
  •  Financials & valuation details for FY24, FY25E, and FY26E.
  •  Revenue, EBITDA, and PAT details for 1QFY25.
  •  Shareholding pattern and CMP: INR 437 TP: INR 505 (+16%) Buy.
  •  Gross margin benefit offset by reduced operating leverage.
  •  Capex benefit to accrue from 2HFY25 onwards.
Login / Open Demat Account to read the report

Never Miss Out on Hot Market Updates

Get exclusive market news delivered to your inbox - on priority